Medical Coverage Policy Gender Reassignment Surgery
Policy documents coverage and guidelines for gender reassignment surgery (GRS) for BlueCHiP for Medicare and Commercial products, including required eligibility documentation, prior authorization requirements, and lists of medically necessary procedures for transwomen and transmen when benefit exists.
No material clinical or coverage changes in this update.
Coverage Summary
This policy covers Gender Reassignment Surgery (GRS) for BlueCHiP for Medicare and Commercial products and is currently effective 2016-07-01 with last update 2018-07-03. Coverage stance is mixed: when a benefit exists and documentation and eligibility criteria are met, a list of GRS procedures is considered medically necessary for transwomen and transmen; cosmetic procedures remain excluded depending on product. Prior authorization is required for BlueCHiP for Medicare and recommended for Commercial groups to determine eligibility and benefits. The policy reflects real-life experience and hormone therapy prerequisites, requiring 12 months of full-time living and working in the desired gender role (real-life experience) and 12 continuous months of hormone therapy prior to considering surgery.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.